<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33560">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02004119</url>
  </required_header>
  <id_info>
    <org_study_id>4577-002</org_study_id>
    <nct_id>NCT02004119</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of KHK4577</brief_title>
  <official_title>Randomized Double-blind Placebo-controlled Study of KHK4577 in Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Company, Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Company, Limited</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an randomized double-blind placebo-controlled study to evaluate the efficacy
      and the safety of oral KHK4577 for 6 weeks in patients with atopic dermatitis.
      Pharmacokinetics of KHK4577 will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent improvement from baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Pre-dose, Week 1,2,4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Investigator's Global Assessment score</measure>
    <time_frame>Pre-dose, Week 1,2,4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index</measure>
    <time_frame>Pre-dose, Week 1,2,4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (itching)</measure>
    <time_frame>Pre-dose, Week 1,2,4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients with adverse events</measure>
    <time_frame>From Day 1 through Week 6</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of pharmacokinetics of plasma KHK4577 concentration</measure>
    <time_frame>pre-dose, Week 1,2,4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KHK4577</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4577</intervention_name>
    <description>&quot;Placebo Experimental : KHK4577&quot;</description>
    <arm_group_label>KHK4577</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has signed voluntarily the written informed consent form to participate in
             this study.

          -  Subject has been diagnosed as atopic dermatitis according to Guidelines for
             Management of Atopic Dermatitis (2009).

          -  Rajka &amp; Langeland criteria of &gt;/= 4.5 at screening visit

          -  Investigator's Global Assessment (IGA) score of &gt;/= 3 at screening visit

        Exclusion Criteria:

          -  Evidence of skin disorders/conditions that would interfere with the assessment of the
             effect of the study drug.

          -  Subject received photochemotherapy or systemic immunosuppressants within 2 weeks
             prior to informed consent.

          -  Subject has any active infectious disease(except localized infection) which needs to
             treat with systemic antibiotics(eg. antibacterial, antifungal or antiviral drugs)
             within 4 weeks prior to informed consent.

          -  Subject has complications / history of drug abuse or alcoholism.

          -  Subject has drug allergy or history of allergic reaction to a drug medicine.

          -  Subject has a significant concurrent medical conditions as defined in the study
             protocol.

          -  Subject is breast-feeding, pregnant or planning to become pregnant in this study
             period.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Hakko Kirin</last_name>
    <email>clinica.info@kyowa-kirin.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KYOWA HAKKO KIRIN</last_name>
      <email>clinical.info@kyowa-kirin.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
